Telehealth Ketamine Legality: National Overview

Telehealth ketamine legality in the United States rests on a mix of federal drug law, DEA telemedicine exemptions, and state-level licensing and pharmacy rules. Ketamine is a Schedule III controlled substance with recognized medical uses, and prescribing it off-label for depression, anxiety, PTSD, and other psychiatric conditions is legal medical practice. Delivering that prescription through a telehealth platform, without a prior in-person exam, is currently allowed under DEA exemptions that have been extended repeatedly since the COVID-19 public health emergency rather than made permanent.

That distinction matters. The temporary nature of the exemption means the rules governing telehealth ketamine legality could tighten once the DEA finalizes its permanent telemedicine regulations. This overview maps the federal framework, the state-by-state variance layered on top of it, and what patients should check before starting or continuing treatment.

Controlled Substances Act

Ketamine is regulated as a Schedule III drug under the Controlled Substances Act (CSA), the federal law that classifies drugs by medical use and abuse potential. Schedule III status means ketamine has accepted medical uses, a lower abuse potential than Schedule I or II substances, and can be prescribed by practitioners who hold a DEA registration. Prescriptions are subject to DEA record-keeping and dispensing requirements.

The Ryan Haight Act

The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 set the baseline rule for controlled substance telehealth: a practitioner generally could not prescribe a controlled substance over the internet without first conducting an in-person evaluation of the patient. This requirement effectively barred a direct-to-consumer telehealth ketamine model for years. The DEA outlines the exceptions to this rule on its guidance page on prescribing controlled substances by internet.

COVID-19 Exemptions and Their Extensions

In March 2020, the DEA issued exemptions under the declared COVID-19 public health emergency that allowed Schedule II-V controlled substances, including ketamine, to be prescribed via telehealth without a prior in-person visit. The telehealth ketamine industry grew substantially during this window. The public health emergency ended in May 2023, and according to the DEA's telemedicine policy page, the agency has extended the telemedicine prescribing flexibilities multiple times since then through periodic rulemaking while it works on a permanent framework. Patients and providers should check that page directly for the current status rather than assuming a past extension is still active.

Federal law sets the floor for telehealth ketamine legality, but states can add requirements on top of it. The legal picture varies by state across several dimensions, and providers must satisfy federal and state rules at the same time.

Provider Licensing

A provider must hold a medical license in the state where the patient is physically located during the visit, not just the state where the provider is based. Providers treating patients across multiple states must hold a license in each one, or practice under an interstate arrangement such as the Interstate Medical Licensure Compact.

State Prescribing Restrictions

Some states have enacted their own rules for controlled substance prescribing that go beyond federal requirements. A provider prescribing ketamine via telehealth into one of these states has to comply with the added state rules, not just CSA and DEA requirements. Our state-by-state ketamine regulations guide breaks down that variance in more detail.

State Telemedicine Practice Standards

States also set the standard of care for telemedicine visits, including documentation, patient consent, and clinical practice standards. Some states require a telemedicine encounter to meet the same standard as an in-person visit; others use a separate telemedicine-specific framework.

Pharmacy Rules

The pharmacy that dispenses compounded ketamine must hold a license to dispense in the patient's state. Compounding pharmacy rules vary by state and can determine whether a particular ketamine formulation can legally reach a patient there.

The telehealth ketamine regulatory environment remains in flux. A few developments are worth watching.

• DEA Special Registration: A permanent rule under the SUPPORT Act framework would set the lasting structure for telehealth controlled substance prescribing, likely including some form of special registration or added accountability requirements for providers.
• State legislative activity: Some states are actively updating their telemedicine laws in response to the shifting federal landscape, which can change requirements independent of any DEA action.
• Congressional activity: Additional legislation affecting telehealth and controlled substances beyond the SUPPORT Act framework remains possible.

Patients and providers should treat the current DEA exemptions as a framework that can change, not a permanent guarantee. See our telehealth law tracker for a closer look at how these changes could play out, and read about the federal investigation into online ketamine sellers for an example of what enforcement looks like when a provider operates outside this legal framework.